The term 'mood stabilizer' is widely used by both patients and professionals in the context of treating bipolar disorder but it is often misunderstood. It essentially denotes bipolar medications, even though for patients with bipolar disorder 'remaining well' necessitates a range of strategies and interventions [1] . It is interesting to note that no regulatory authority has ever approved any drug for this indication and for most clinicians the term 'mood stabilizer' means either lithium or divalproate. The importance of the term has been magnified by the suggestion in important US guidelines that a mood stabilizer should be used in all stages of bipolar treatment [2] . In recent years the use of the term has been extended to other psychopharmacological medicines in a way that is at times unhelpful and at other times simply reflects increasing knowledge of the action of new agents with the potential to stabilize mood. Therefore the definition of what we mean by a mood stabilizer and how we use the term has gained heightened interest, and, given a lifetime prevalence of 2.5% for bipolar I and II disorder, this is an issue that has profound clinical salience [3] .
If we understood the pathophysiology of bipolar disorder we might reasonably expect to define the actions that would be effective in treating it and so in stabilizing mood. At present, however, pragmatic definitions of a mood stabilizer dominate our thinking. This follows from the way in which pharmacological ideas develop in psychiatry. As a rule clinical actions have been discovered before underlying mechanisms have been understood. That trend continues and reflects the converse of the ideal process usually described for experimental medicine and pathology. It therefore means that clinical observations of what medicines do are critical to how we classify them. In the case of the mood stabilizers it will be worth considering the kinds of clinical actions that contribute to our understanding of mood stability ( Figure 1 ).
Clinical actions of mood stabilizers

Effects of short-term treatment
Efficacy in acute mania and acute depression
It is clearly quite reasonable to imagine that any medicine effective in acute mania and depression would in effect stabilize mood. The extrapolation is plausible and the possibility is real but there are two aspects of this view that are questionable. First, for practical reasons relating to implementation and monitoring, acute treatments may not be particularly suitable for prescription long term. Electroconvulsive therapy (ECT), for instance, is a good example of a treatment that is effective acutely in both bipolar depression and mania but extension of this treatment, while sometimes carried out as a last resort, is not a convenient or desirable procedure for outpatient management. Further, acute side-effects of treatment are less problematic when the illness is at its nadir because they are comparatively less pronounced but, in general, as illness-related symptoms remit sideeffects of acute treatments become less acceptable and less likely to be tolerated long term. Second, we lack adequate acute and continuation data, especially in depression. The profile of a variety of medicines in the acute treatment of mania and depression is shown in Table 1 . The majority of current medicines were initially studied as anti-manic agents and only in a few cases have they been adequately assessed for the treatment of bipolar depression [4] . With respect to the latter the most important studies have been conducted for the antipsychotics, olanzapine and quetiapine, both of which have successfully shown separation from placebo [5, 7, 8] .
In an attempt to define the parameters of a mood stabilizer Bauer and Mitchner have proposed a 2)2 model wherein efficacy should be demonstrated in both acute and long-term studies for both mania and depression [9] . In their purview they identify lithium as the only medicament meeting this exacting definition. As already indicated, a greater emphasis on the long term may be preferable and there is reason to be more sceptical of the acute credentials of lithium in bipolar depression [10] .
Finally, while acute effects may be regarded as a useful proof of concept for putative mood stabilizers, it would be questionable should medicines be extended to the long-term setting simply on the basis of short-term efficacy in mania and depression. This is particularly the case with regard to atypical antipsychotics, because safety concerns are continuing to rise with regard to the metabolic syndrome and potential impact upon cognition [11] . Another consideration in this context is the exacerbation of the opposing pole of the illness.
Efficacy in treating mania or depression without exacerbating the opposing pole of the illness
This definition of a mood stabilizer emphasizes the conservation of treatment effects gained in an acute episode and assumes that continuation of treatment is the paradigm under which most clinicians work. The difficulty with using this particular definition is that few properly controlled trials of continuation treatment have ever been conducted. The challenge is that to initiate an acute treatment trial with placebo usually requires a design that stops the placebo after a finite period. However, to fully understand the continuation phase, indefinite treatment with placebo 
', approximate efficacy in the two phases of bipolar illness. For further details see [4 Á6 ].
is required, which in practice is difficult to implement and ethically questionable. Therefore, the assumption that we know the outcomes of acute treatment for mania and depression for different agents is misleading. There are, in fact, few controlled data on whether one agent is more or less likely than another to result in depression following mania or vice versa. These considerations are perhaps even more poignant in the treatment of bipolar mixed states and rapid cycling [12] .
Efficacy in the stabilization of rapid cycling mood disorder
Rapid cycling is a core specifier for bipolar disorder and is usually regarded as an indication that patients will be difficult to treat. Moreover, many rapid cycling patients cycle continuously and hence lack any mood stability. Rapid cycling patients may therefore provide a particularly severe test criterion for a mood stabilizer as in the case of quetiapine [13] . Moreover, any new medicines showing particular efficacy in rapid cycling might be expected to do well in more conventional relapse prevention studies that usually enrol less severely ill patients. However, this prediction has not been adequately tested in practice.
There are a limited number of studies of rapid cycling patients. An open-label study suggested the efficacy of divalproate [14] , while a placebo-controlled study showed weak efficacy for lamotrigine [15] . However, the effects of lamotrigine were if anything more prominent in patients with bipolar II disorder than in patents with bipolar I disorder. This raises a caveat to extrapolating from findings in patients with rapid cycling bipolar disorder to more general aspects of mood stabilization. The higher efficacy in patients with bipolar II disorder may reflect the weaker effects of lamotrigine against manic relapse. Because many rapid cycling patients suffer from bipolar II disorder, it could bias trials in which rapid cyclers are overrepresented, in turn favouring drugs with weak anti-manic actions.
Effects of long-term treatment
Efficacy in preventing recurrence of mania and depression with maintenance treatment
It is now widely accepted that the major challenge in treating bipolar disorder lies less in shortening the duration of acute episodes, a goal towards which some measure of success has been achieved, and more towards the prevention of new episodes occurring in the long-term treatment of individual patients [16] . Table 2 shows the medicines that are currently best characterized with regard to relapse prevention. In other words they have been studied in circumstances in which groups of patients with bipolar disorder have been recruited when well, often following an acute episode, then randomized either to continue on an active treatment or placebo. Such studies are difficult to do and have demanded, for both ethical and practical reasons, the adoption of softer endpoints than originally used in the earlier lithium studies. In the latter, hospital admission was a common end-point. In current studies either the recrudescence of symptoms or the need of a new intervention for a new mood episode is used to denote outcome, namely recurrence.
Lithium continues to serve as the reference mood stabilizer. It was the first to be studied under randomized placebo-controlled conditions [17] and its efficacy has been re-established, one could say, by contemporary studies in which it has been added as a comparator to studies of divalproate and lamotrigine [18, 19] . In contrast to many of the earlier studies that included patients with major depression, these new findings for lithium, from exclusively bipolar disorder trials, have been summarized by Geddes et al . [20] . The numbers of patients randomized, although not exceptionally large, are of sufficient size to allow reasonable confidence in the results. The summary findings suggest an overall risk ratio for prevention of a new mood episode of 0.65 (95% confidence intervals: 0.50 Á0.84) or an absolute reduction in risk of 20% compared to placebo. The effects against mania were noticeably more impressive than effects against depression but lithium continues to have a reputation for reducing the risk of suicide in patients with bipolar disorder as compared both to placebo and comparators such as carbamazepine. Indeed, when all the available data were reviewed by Cipriani et al ., the effect on both suicide and overall mortality was statistically significant [21] . For these reasons, and the independence of the trials conducted on Olanzapine and other atypicals lithium, it still merits its position as the benchmark treatment in bipolar disorder and the mood stabilizer of choice. But it is not of overwhelming efficacy in the majority of patients and the other agents that we now have are important and welcome Á whether used as an alternative to, or in combination with, lithium.
Divalproate was one of the first of these new alternatives to be studied and has trials demonstrating efficacy in acute mania and trends towards efficacy in relapse prevention [22, 23] . Unfortunately the relapse prevention study was conducted at a time when an over-conservative design was adopted. Thus, only secondary analysis of the Bowden et al . maintenance study [23] showed positive effects, although the magnitude of the main treatment effect is comparable to that of lithium. Learning from these methodological issues, the lamotrigine maintenance studies used softer but nevertheless clinically meaningful end-points such as time to intervention for a mood episode, and demonstrated a separation from placebo by both lithium and lamotrigine arms in the relevant studies. Two trials were conducted that recruited patients either with acute mania or acute depression. The overall effects that have been demonstrated in a pooled analysis show that, on average, lithium was more effective against mania than against depression, while for lamotrigine the results were the converse: it was more effective against depression than against mania [24] . Subsequent relapse prevention studies have also been completed for olanzapine and some of the other atypical antipsychotics. In the case of olanzapine, efficacy again seems to favour mania rather than depression.
Efficacy in prevention of occurrence of mania and depression
Preventing the onset of bipolar illness is the ultimate in prophylaxis. It is a goal shared by many and an ideal can be realized only with a better clinical and basic understanding of bipolar disorder pathophysiology. It is not unreasonable, however, to foresee the development of medications that act in prophylaxis to maintain mood stability and prevent the occurrence of bipolar depression or mania in those who are prone to the illness. It is quite possible that some medications used presently as mood stabilizers have some capacity in this regard [25] but, in the absence of means for evaluating such prophylactic actions, treating the acute phases of bipolar disorder and maintaining wellness remain the focus of current research.
Discussion
At present we depend upon pragmatic observation from clinical trials to define the actions of the agents we use in psychopharmacology. A key question is whether mood stabilization is a class effect of certain groups of medicines. Whether or not they form groups with common actions that help define common treatment effects and possibly even the locus of psychopathology within the neural axis, is an interesting proposition. There was clearly a phase in research when all anticonvulsants were seen as potential mood stabilizers and novel anticonvulsants are probably worth investigating in bipolar disorder [6] . But this approach does not stem from an understanding of how they might work in modifying disturbances of mood. The idea that bipolar disorder has something in common with epilepsy remains impressionistic, rather than mechanistic and is confounded by the fact that producing seizures using ECT is therapeutic. Furthermore, we already know that the designation of both topiramate and gabapentin as mood stabilizers was premature because neither have shown convincing efficacy in short-term treatment studies.
Regardless of agent or phase of illness the majority of treatment trials in bipolar disorder examine the efficacy of monotherapy, whereas in practice most patients will try medication combinations and are often maintained long term on two or more drugs [4] . This gulf between research and clinical practice is reflected in the variety of recommendations made by treatment guidelines [26] and the findings of recent research studies. For instance, atypical antipsychotics in combination with mood stabilizers appear to be the most efficacious treatment for acute mania [27] , whereas antidepressant therapy as an adjunct to a mood stabilizer does not seem to confer additional benefit [28] . Clearly, future studies need to examine real-world treatment and perhaps consider combinations of medications as putative mood stabilizers.
Against this background the use of the term 'mood stabilizer' as a synonym only for lithium and divalproate looks increasingly idiosyncratic. Almost any specific more focused definition will include other treatments. The challenge is to use the term in a way that is not so inclusive that it undermines its potential value. The term 'mood stabilizer' has intrinsic value, in part because it prompts clinicians and patients to think beyond the immediate episode, and also because it is a useful branding term. Brands clearly have commercial value, but in a medical context branding is important because it facilitates the reinforcement of health messages. Now, in the bipolar illness course, we emphasize long-term treatment from as early as possible [29] . Given the difficulties in early detection and diagnosis of bipolar disorder and then the problems of initiating suitable treatment and maintaining adherence, the goal of achieving successful early intervention is an ambitious endeavour and one that demands all the help in communication we can muster. To this end the designation 'mood stabilizer' is likely to be of considerable assistance not least because of its inherent appeal and, as such, it is an asset that we should not relinquish prematurely. In the last decade many potential mood stabilizers have risen only to fall, suggesting that it is an unstable time for mood stabilizers but one that will bear advantage to those that seek mood stability.
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